Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...

TORONTO -- An investigational subcutaneous autoinjector showed comparable efficacy and safety to the IV formulation of ...

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after more than three ...

After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, ...

Biogen raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare ...

A month away from the PDUFA decision date for a Leqembi (lecanemab) subcutaneous autoinjector to be used for maintenance ...

Eisai updates Leqembi® outlook for fiscal year 2024 (April 2024 - March 2025). Sales now expected to reach JPY 42.5 billion Nov. 07, 2024 11:19 PM ET Barnes Group Inc. (B), BIOA ...

--BioArctic AB's partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion for their fiscal year 2025, corresponding to a 73 percent growth compared to the previous ...

Eisai: Leqembi Approved In EU (Rating Downgrade) Jun. 10, 2025 2:46 AM ET Eisai Co., Ltd. (ESALF) Stock, ESAIY Stock ESALF, ESAIY Valkyrie Trading Society Investing Group Leader ...